Introduction
Polymorphic human cytochrome P450 (P450) enzymes have been well characterized and are involved in the oxidative metabolism of a variety of endogenous and exogenous compounds. Individual differences in drug metabolism may be caused predominantly by impaired P450 variants or whole gene deletion, as extensively reported in humans (Ingelman-Sundberg and Sim, 2010) . In addition, a nomenclature system for polymorphic human P450 alleles (http://www.cypalleles.ki.se/) has been established. Non-human primates are generally used for preclinical studies in order to predict the pharmacokinetics and toxicity of new drug candidates due to their physiological and genetic similarity to
humans. The Old World Monkeys such as cynomolgus monkeys (Macaca fascicularis)
are the most frequently used among the non-human primate species. Cynomolgus monkey P450 2C9 (Uno et al., 2015a) , 2C19 (Uno et al., 2014a; Utoh et al., 2015) , 2C76 (Uno et al., 2009), and 2D6 (Uno et al., 2014b; Uno et al., 2015b) are polymorphic in drug metabolism, similar to human P450s. Furthermore, development of a genotyping tool for a functionally relevant P450 2C19 allele (p.Phe100Asn; p.Ala103Val; p.Ile112Leu) in cynomolgus macaques was recently reported (Uno et al., 2014a; Uno and Yamazaki, 2016) . One of the New World Monkeys, the common marmoset (Callithrix jacchus), , is used in various research fields such as drug metabolism because of advantageous features including their small body size (Sasaki, 2015) . Gene expression of marmoset P450 1A, 2A, 2B, 2C, 2D, 2E, 2J , and 3A in livers was reported (Shimizu et al., 2014) , but genetic polymorphisms in marmoset drug metabolism have not been investigated so far.
In humans, the study of pharmacokinetics using caffeine, S-warfarin, omeprazole, metoprolol, and midazolam, in combination, as probe substrates of P450 1A2, 2C9, 2C19, 2D6, and 3A, respectively, has been reported (Turpault et al., 2009) and clinically important anticoagulant drug S-warfarin is a typical human P450 2C9 substrate (Yamazaki and Shimada, 1997) . Cynomolgus monkey P450 2C19 has high activity toward R-warfarin 7-hydroxylation (Hosoi et al., 2012) , whereas marmoset P450 2C19 efficiently catalyzes S-warfarin 7-hydroxylation (Uehara et al., 2015) . Inter-animal variations of R-warfarin clearance in cynomolgus monkeys are accounted for by the monkey P450 2C19 et al., 2014a; Utoh et al., 2015) . Additionally, the previous study indicated that optical resolution for plasma concentrations of S-warfarin in marmosets rapidly decreased than those of R-warfarin after intravenous administration of racemic warfarin, indicating that S-warfarin is stereo-selectively metabolized in marmoset livers, similar to human livers (Uehara et al., 2016) , as mean values. Metabolic clearance of S-warfarin in marmosets in the previous study exhibited larger inter-individual variations than that of R-warfarin (Uehara et al., 2015) , suggesting the possible genetic polymorphisms of marmoset P450 2C19. The characterization of polymorphic marmoset P450 enzymes is of use for understanding the catalytic function of marmosets.
In this study, resequencing of the marmoset P450 2C19 gene identified three variants [p.(Phe7Leu; p.Ser254Leu; p.Ile469Thr) ] that showed substantially reduced activity compared with wild type P450 2C19 in S-warfarin 7-hydroxylation. We also report on the marmoset P450 2C19 polymorphism in R/S-warfarin 7-hydroxylation catalyzed by 18 marmoset livers in vitro and R/S-warfarin clearance in plasma from 6 marmosets in vivo. Kinetic analysis for S-warfarin 7-hydroxylation suggested that recombinant marmoset P450 2C19 Ser254Leu variant would change the metabolic capacity of marmoset liver P450 2C19.
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Materials and Methods

Chemicals and enzymes
S/R-warfarin and 7-hydroxywarfarin were purchased from Sigma-Aldrich (Tokyo, Japan).
Oligonucleotides were synthesized by Greiner Japan (Tokyo, Japan). Liver microsomes were prepared from individual tissue samples derived from marmosets as described previously (Uehara et al., 2015) . The other chemicals were used in the highest grade commercially available.
Genotyping and plasma preparations
Twenty-four marmosets (males, >2 years old) were obtained from CLEA Japan (Tokyo, Japan Sequence analyses were conducted using DNASIS Pro (Hitachi Software, Tokyo, Japan) and Sequencer (Gene Codes, Ann Arbor, MI). Genetic variants were determined by comparison of the sequence with the marmoset P450 2C19 cDNA sequence (Uehara et al., 2015) .
Two marmosets were subjected to oral and intravenous administration of a five-drug Pharmacokinetic parameters were derived from the respective plasma concentrations versus time curves using non-compartmental analysis in Phoenix WinNonlin® 6.1 (Pharsight, Mountain View, CA). The warfarin doses divided by 2 for intravenous and oral administration were used for the calculations of the pharmacokinetic parameters of R-and
S-warfarin.
This article has not been copyedited and formatted. The final version may differ from this version. (Gillam et al., 1993; Dong et al., 1996) that has been incorporated into the expression vector to enhance protein expression.
The primer pairs used were 5′-AGAACACCAAGAATTGGTAGACATTAACA-3′ and 5′-TGTTAATGTCTACCAATTCTTGGTGTTCT-3′ for c.761C>T; and 5′-CAAAAACCTTGACACCACTCCAGTTGTCA-3′ and 5′-TGACAACTGGAGTGGTGTCAAGGTTTTTG-3′ for c.1406T>C. Sequences of the entire inserts were confirmed by sequencing with an ABI PRISM 3730 DNA Analyzer (Applied Biosystems). PCR products were subcloned into pCW vectors containing human NADPH-P450 reductase cDNA as described previously (Uehara et al., 2015) . The membrane fractions were prepared from E. coli expressing P450 2C19 proteins, and the concentrations of P450 protein and NADPH-P450 reductase were measured as described previously (Uehara et al., 2015) . Similar expression levels of recombinant P450 2C19
wild-type and Ser254Leu variant proteins were also confirmed using anti-human P450 2C9
antibodies (Corning Life Sciences, Woburn, MA) in the immunoblotting system described previously (Uehara et al., 2015) . S/R-Warfarin 7-hydroxylation activities at substrate concentrations of 10 and 100 µM, unless otherwise specified, by recombinant marmoset P450
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Plasma concentrations of R-warfarin (determined after chiral separation) were similar between the homozygous and wild-type groups up to 24 h after the intravenous (Fig. 1B) and oral ( Fig. 1D ) administrations of warfarin under the present conditions. However, S-warfarin depletion from plasma was faster in the wild-type group compared to the homozygous group after the intravenous (Fig. 1A) and oral ( Fig. 1C) administrations of racemic warfarin.
Calculated mean pharmacokinetic parameters for S-and R-warfarin in the three wild-type and three homozygous marmosets are summarized in Tables 2 and 3 . No significant effects of the genotype were seen on the kinetic parameters of in vivo pharmacokinetics of R-warfarin in the wild-type and homozygous mutant groups (Table 2 ). For the same animal groups, in contrast, significant effects of the genotype (p < 0.05) were observed on the elimination half-lives (t 1/2 ), area under the curves (AUC), and clearance values of S-warfarin (Table 2) . Similarly, kinetic parameters for R-warfarin orally administered were not This article has not been copyedited and formatted. The final version may differ from this version. (Table 3) ; however, mean values of t 1/2 and AUC in the homozygous group were significantly higher than those of the wild-type group (Table 3) .
R/S-Warfarin 7-hydroxylation activities mediated by eighteen marmoset liver microsomes were determined in vitro. One-way ANOVA revealed no significant effects of the genotype on R-warfarin 7-hydroxylation activities among the wild-type, heterozygous, or homozygous groups ( Fig. 2A) . Among the same animal groups, in contrast, significant effects of the genotype (p < 0.05) were observed on S-warfarin 7-hydroxylation activities at substrate concentrations of 10 µM (Fig. 2B ) and 100 µM (Fig. 2C) . Mean values of S-warfarin 7-hydroxylation activities at 10 µM in the heterozygous and homozygous mutant groups were significantly lower than that of the wild-type group as shown by one-way ANOVA post tests (Fig. 2B) ; the mean S-warfarin 7-hydroxylation activities (at 100 µM) of the homozygous group was significantly lower than that of the wild-type group (Fig. 2C ).
Recombinant marmoset P450 2C19 wild-type enzyme showed a similar affinity (K m, 14 ± 1 μ M) but higher V max (334 ± 5 min -1 ) rates for S-warfarin 7-hydroxylation as compared to P450 2C19 Ser254Leu variant protein (K m, 12 ± 2 μ M; V max , 61 ± 1 min -1 ) (Fig. 3) . Because marmoset P450 2C19 Ile469Thr variant protein in bacterial membrane preparations did not show any CO-difference spectra or immunoreactive bands with commercial anti-human P450 2C9 antibodies, its catalytic function could not be evaluated under the current conditions. This article has not been copyedited and formatted. The final version may differ from this version. It is well-known that human P450 genetic variants (http://www.cypalleles.ki.se/) may cause inter-individual differences in pharmacokinetics or toxicokinetics of drugs.
Whole-genome sequencing has indicated the genetic divergence of marmosets (Sato et al., 2015) . Indeed, in the current study, genetic variants of marmoset P450 2C19 [p.(Phe7Leu;  p.Ser254Leu; p.Ile469Thr)] were found by direct sequencing of 18 marmoset genomes ( Based on our recent paper describing roles of marmoset P450 2C19 in warfarin oxidation (Uehara et al., 2015) , in this present study, the novel marmoset P450 2C19 variant Four wild-type, six heterozygous, and eight homozygous marmosets for P450 2C19
[p.(Phe7Leu; p.Ser254Leu; p.Ile469Thr)] were used. Individual (plots) and mean (bars) from 18 marmosets were analyzed (*p < 0.05, one-way ANOVA with Dunnett's post tests, as compared to the wild-type group). Table 1 The primers used for amplification of marmoset P450 2C19. 
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